Although the atherosclerotic CV disease risk reduction and CKD progression benefits of SGLT-2 inhibitors may be found to be a class effect in future, the evidence for ertugliflozin (a third SGLT-2 inhibitor recently deleted from the market in Australia) is less robust with further studies ongoing
Gently swirl until completely dissolved, do not shake it vigorously, as this could damage the delicate peptide structure
Photo reference for normal appearance Three photos to add as image carousel on this page: Photo 1: "What clear semaglutide looks like." A standard 5 mL multi-dose vial of B12-free compounded semaglutide held against a white background
The SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight and demonstrated weight loss of 15 percent at the 5 mg dose, 19.5 percent at the 10 mg dose, and 20.9 percent at the 15 mg dose over 72 weeks
Clinical studies, such as the SURMOUNT trials, provide a helpful benchmark for what is realistic
Suitable for first-time GLP-1 users or those sensitive to GI side-effects